ArticleMedicina oral, patologia oral y cirugia bucal2026
Rhinocerebral mucormycosis: A 15-year retrospective study in southern Spain.
Article in Medicina oral, patologia oral y cirugia bucal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRhinocerebral mucormycosis (RCM) is a severe, rapidly progressing opportunistic fungal infection with a high mortality rate, primarily affecting immunocompromised patients with diabetes mellitus or haematological malignancies. Its incidence has increased in recent years, particularly since the SARS-CoV-2 pandemic, coinciding with population ageing and the growing prevalence of immunocompromised patients. Data regarding survival rates and the most effective diagnostic and therapeutic strategies in Spain are limited. This study analyses the clinical characteristics, risk factors, and prognosis of RCM at a tertiary care centre in southern Spain. MATERIAL AND
methodsA retrospective study was conducted on 36 patients treated for RCM between 2009 and 2023. Clinical-epidemiological variables, history of immunosuppression, extent of infection, diagnostic and therapeutic management, and survival outcomes were evaluated. Statistical analysis was performed using chi-square tests and regression models (p<0.05).
resultsMales predominated (66.7%), with a mean age of 58 years (range 17-83). The primary risk factors were haematological malignancies (61.1%), solid tumours (16.6%), and uncontrolled diabetes mellitus (22.2%). The most common clinical presentation was orbital involvement (86.1%), followed by sinusitis (47.2%), neurological symptoms (36.1%), and palatal necrosis (25%). Imaging studies revealed pansinusitis in 97.2% of cases and periorbital/nasomaxillary cellulitis in 66.7%. Treatment consisted of combined antifungal therapy (liposomal amphotericin B/azoles) and management of the underlying disease. Twenty-seven patients (75%) underwent surgical intervention, including endoscopic sinus surgery, maxillectomy, or orbital exenteration. Overall mortality was 66.7% (24 deaths), which was significantly associated with advanced age and the absence of surgical treatment.
conclusionsRCM is a rare but highly lethal infection in our setting. Early diagnosis and prompt combined treatment, involving multidisciplinary management and standardised protocols, are essential to improve outcomes. The main prognostic factors identified were age, control of immunosuppression, and timely surgical intervention. Further multicentre studies are needed to optimise treatment strategies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.